<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0001799'>Viral</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> has been shown to induce <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, unidentified types of <z:hpo ids='HP_0012115'>hepatitis</z:hpo> being the most common cause for <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>-associated <z:hpo ids='HP_0006562'>viral hepatitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The survival rate for this group of patients after bone marrow transplantation with stem cells from an HLA-matched sibling is not well known </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to determine the prevalence of <z:hpo ids='HP_0012115'>hepatitis</z:hpo> G virus (HGV) and transfusion transmitted virus (TTV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> in non-A, non-B, non-C <z:hpo ids='HP_0012115'>hepatitis</z:hpo> associated-<z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (HAAA) patients, and to define the role of bone marrow transplantation (BMT) as a therapeutic modality for this disease </plain></SENT>
<SENT sid="3" pm="."><plain>Sixty-eight patients (43 males and 25 females) with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, underwent allogeneic BMT at the Hadassah University Hospital between 1981 and 1997 </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0003674'>Onset</z:hpo> of <z:hpo ids='HP_0012115'>hepatitis</z:hpo> was defined as <z:hpo ids='HP_0000952'>jaundice</z:hpo> and elevated alanine aminotransaminase (ALT) levels </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0003674'>Onset</z:hpo> of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> was defined as the first date on which varying degrees of <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> occurred: <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> level below 10 g/dl, WBC below 2 x 10(9)/l and <z:hpo ids='HP_0001873'>low platelet count</z:hpo> 10 x 10(10)/l </plain></SENT>
<SENT sid="6" pm="."><plain>Serial serum samples from HAAA patients were assayed for virological and/or serological markers of <z:hpo ids='HP_0012115'>hepatitis</z:hpo> A, B, C, D, E, G viruses, TTV and parvovirus B19 </plain></SENT>
<SENT sid="7" pm="."><plain>Seventeen of the 68 patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (25%) suffered from <z:hpo ids='HP_0012115'>hepatitis</z:hpo>, 12 males and five females, ages 5 to 36 years </plain></SENT>
<SENT sid="8" pm="."><plain>The mean interval between <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0012115'>hepatitis</z:hpo> and first indication of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> was 62 days (range 14-225 days) </plain></SENT>
<SENT sid="9" pm="."><plain>The development of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> was unrelated to age, sex or severity of <z:hpo ids='HP_0012115'>hepatitis</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Ten of the 17 patients (59%) achieved complete ALT recovery prior to the diagnosis of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Serum samples were available for 15 patients; none had evidence of <z:hpo ids='HP_0011009'>acute</z:hpo> or active <z:hpo ids='HP_0012115'>hepatitis</z:hpo> A, B, C, D, E, G and TTV <z:e sem="disease" ids="C0042769" disease_type="Disease or Syndrome" abbrv="">virus infection</z:e> at the time of diagnosis </plain></SENT>
<SENT sid="12" pm="."><plain>Parvovirus B19 DNA sequences were not detectable in 10 of 12 tested cases; two positive results were detected in serum samples obtained after blood transfusion, making the analysis of these positive results difficult </plain></SENT>
<SENT sid="13" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 17 patients underwent BMT </plain></SENT>
<SENT sid="14" pm="."><plain>The mean post-BMT follow-up period was 38 months (range 1 day-123 months), five patients (30%) died 1 to 160 days post BMT, and 12 (70%) are alive 31 to 123 months after BMT </plain></SENT>
<SENT sid="15" pm="."><plain>Relapsing <z:hpo ids='HP_0012115'>hepatitis</z:hpo> was not observed in any of the patients </plain></SENT>
<SENT sid="16" pm="."><plain>In conclusion, HAAA is a disease of the young and the etiologic agent associated with HAAA remains unknown </plain></SENT>
<SENT sid="17" pm="."><plain>HGV, TTV and parvovirus B19 sequences were not detected in any of the HAAA cases </plain></SENT>
<SENT sid="18" pm="."><plain>The survival rate after BMT with stem cells from an HLA-matched sibling is similar to that for patients with non-<z:hpo ids='HP_0012115'>hepatitis</z:hpo>-associated <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
</text></document>